Protein Discovery Linked to Rare Inflammatory Syndrome
Researchers identified two proteins that cause cell rupture in patients with cryopyrin-associated periodic syndrome.
Updated on Oct. 14, 2026 in Diseases — General
Live Poll
Is it time for medical research to focus on targeting cell-rupture proteins instead of signaling blockers?
Scientists have determined that gasdermin D and gasdermin E proteins drive neutrophil rupture in patients with cryopyrin-associated periodic syndrome (CAPS). This finding identifies a potential new therapeutic target for this rare group of inherited inflammatory disorders.
Why it matters
Understanding the mechanism of neutrophil bursting could eventually lead to new treatment options for those managing CAPS. This discovery provides clarity on how pore-forming proteins influence inflammation and the release of IL-1beta in these patients.
A study published on October 13, 2026, in Science Signaling utilized mass cytometry on neutrophils from 6 CAPS patients and 6 healthy donors. Results showed gasdermin D is the primary driver of cell rupture, while gasdermin E contributes when gasdermin D is non-functional.
The players
University of California, San Diego
This academic institution led the research team in identifying the role of gasdermin proteins in neutrophil rupture.
The details
The NLRP3 gene mutation leads to unusually high levels of IL-1beta within neutrophils. In this condition, gasdermin D and E cluster at the cell membrane to form pores, which causes the membrane to stiffen and tear. Researchers observed that removing both proteins in mouse models effectively reduced inflammation and improved survival rates.
Timeline
October 13, 2026: Findings were published in Science Signaling.
Health Landscape
This research provides a deeper molecular understanding of how the NLRP3 gene mutation leads to systemic inflammation. It builds upon existing knowledge of inflammasomopathies, shifting the focus from general inflammation to the specific role of pore-forming proteins.
While these findings are preliminary, they represent a significant step in identifying future therapeutic targets for rare inflammatory disorders. If you are currently managing a diagnosis of CAPS, it is worth discussing the latest developments in inflammasome research with your specialist.
The takeaway
The study clarifies that gasdermin D and E are the mechanical drivers of neutrophil death in CAPS patients. Future treatments may eventually focus on these proteins to manage inflammation, so continue to follow up with your rheumatologist regarding new research developments.
Further reading
Learn more about the latest research on inflammatory conditions in our Diseases — General section.
Source note: This article includes information reported by Inside Precision Medicine.
Live Poll
Is it time for medical research to focus on targeting cell-rupture proteins instead of signaling blockers?
